Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 293

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 293
---
. Quantitively, the APx Board considered that many comparable companies with significantly higher valuations incurred significant operating losses inherent in their respective EBITDA metrics, suggesting an inefficient operating model and making OmnigenicsAI’s valuation attractive in comparison, particularly given its ability to efficiently commercialize and scale. Additionally, as OmnigenicsAI’s unique, multi -facetedproduct offering make it difficult to compare to compare to other companies, and its peers who participate in one or more of its core competencies operate in emerging industries, EBITDA and revenue are not always reliable metrics for evaluation and comparison. Therefore, in analyzing OmnigenicsAI’s valuation, the APx Board took into consideration other factors, such as its ability to commercialize and scale, its total addressable market, its intellectual property portfolio and its unique, multi -facetedbusiness model. In estimating OmnigenicsAI’s total addressable market, the populations of 100 major Latin American cities were considered, each adjusted for the percentage of the population that is likely to be able to access out -of-pockethealth care. • Due Diligence. The results of APx’s due diligence investigation of the Company’s conducted by APx’s management team, Sponsor group and its advisors. • Negotiated Transaction. The financial and other terms of the Business Combination Agreement are reasonable, based on the experience of APx’s management team which has extensive experience in transactions involving special purpose acquisition companies, as assisted by its legal and other advisors, do not include a cash closing condition, and are the product of arm’s -lengthnegotiations between the parties thereto. The APx Board also considered a variety of uncertainties and risk and other potentially negative factors concerning the Business Combination including, but not limited to, the following: • Benefits May Not Be Achieved. The risk that the potential benefits of the Business Combination may not be fully achieved or may not be achieved within the expected timeframe; • Redemption Risk. The risk that a significant number of APx’s shareholders may elect to redeem their shares prior to the consummation of the Business Combination pursuant to the Existing Governing Documents; • APx Shareholders Receiving a Minority Position. The fact that APx’s shareholders will hold a minority position in Holdco; • Fees and Expenses. The significant fees and expenses associated with completing the Business Combination and the substantial time and effort of APx’s management required to complete the Business Combination; • No Third -Party Fairness Opinion. The risk that APx did not obtain a fairness opinion